Antibiotic exposure leads to massive selective pressures that initiate the emergence and spread of antibiotic resistance in commensal and pathogenic bacteria. The slow process of developing new antibiotics makes this approach counterintuitive for combatting the rapid emergence of new antibiotic resistant pathogens. Therefore, alternative approaches such as, the development of nucleic acid-based anti-bacterial treatments, anti-bacterial peptides, bacteriocins, anti-virulence compounds and bacteriophage therapies should be exploited to cope infections caused by resistant superbugs. In this editorial, we discuss how the newly popular CRISPR-Cas system has been applied to combat antibiotic resistance.

中文翻译：

---

CRISPR-Cas系统：应对抗生素耐药性的潜在替代工具。

暴露于抗生素会导致巨大的选择性压力，从而引发共生细菌和致病细菌中抗生素耐药性的出现和扩散。开发新抗生素的过程缓慢，使得这种方法与新出现的抗药性病原体的快速出现作斗争是违反直觉的。因此，应该利用其他方法，例如开发基于核酸的抗菌治疗，抗菌肽，细菌素，抗毒力化合物和噬菌体疗法，以应对由抗性超级细菌引起的感染。在这篇社论中，我们讨论了如何将新近流行的CRISPR-Cas系统应用于抗药性。